Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News enVVeno Medical Corp NVNO

Healthcare Medical Devices
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system... see more

Recent & Breaking News (NDAQ:NVNO)

enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference

Accesswire January 20, 2022

enVVeno Medical to Present at the Virtual Investor Roundtable Event

Accesswire November 16, 2021

enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Accesswire November 11, 2021

JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th

Accesswire November 4, 2021

enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial

Accesswire October 22, 2021

enVVeno Medical Corporation Successfully Completes Rebranding

Accesswire October 1, 2021

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Accesswire September 24, 2021

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Accesswire September 21, 2021

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Accesswire September 15, 2021

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Accesswire September 7, 2021

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Accesswire August 19, 2021

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Accesswire August 3, 2021

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Accesswire July 8, 2021

CEO Presenting on the Emerging Growth Conference on May 12. Register here

GlobeNewswire May 10, 2021

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Accesswire April 23, 2021

First U.S. Patent Issues on Hancock Jaffe VenoValve

Accesswire April 7, 2021

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Accesswire April 5, 2021

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Accesswire March 8, 2021

First U.S. Patent Allowed on Hancock Jaffe VenoValve

Accesswire February 24, 2021

Hancock Jaffe Completes $41 Million Public Offering

Accesswire February 11, 2021